Fosinopril/hydrochlorothiazide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 39: | Line 39: | ||
FDA modified its labeling on February, 2009 to include a precaution of drug interaction with gold. "Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold ([[sodium aurothiomalate]]) and concomitant ACE inhibitor therapy including MONOPRIL/ MONOPRIL HCT."<ref>{{cite web|title=Monopril HCT (fosinopril/hydrochlorothiazide) 20/12.5mg and 10/12.5mg Tablets February 2009|url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm133086.htm|publisher=FDA}}</ref> |
FDA modified its labeling on February, 2009 to include a precaution of drug interaction with gold. "Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold ([[sodium aurothiomalate]]) and concomitant ACE inhibitor therapy including MONOPRIL/ MONOPRIL HCT."<ref>{{cite web|title=Monopril HCT (fosinopril/hydrochlorothiazide) 20/12.5mg and 10/12.5mg Tablets February 2009|url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm133086.htm|publisher=FDA}}</ref> |
||
==Dosage== |
|||
The recommended initial dosage of Fosinopril/hydrochlorothiazide for adults with high blood pressure (hypertension) is losartan-hydrochlorothiazide 10 mg/12.5 mg per day. The dosage range could be 10-80 mg/12.5-50 mg once a day. |
|||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
||
{{Agents acting on the renin-angiotensin system}} |
|||
{{DEFAULTSORT:Fosinopril hydrochlorothiazide}} |
{{DEFAULTSORT:Fosinopril hydrochlorothiazide}} |
||
Revision as of 06:15, 13 December 2013
| Combination of | |
|---|---|
| Fosinopril | Angiotensin converting enzyme inhibitor |
| Hydrochlorothiazide | Thiazide diuretic |
| Clinical data | |
| Trade names | Monopril HCT |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
Fosinopril/hydrochlorothiazide is the combination preparation of fosinopril, an angiotensin converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic. It is a combination drug to treat high blood pressure (hypertension)[1] The other similar drug in UAS is Losartan/hydrochlorothiazide (Hyzaar).
This drug has a boxed warning about its significant risk to cause fetal/neonatal morbidity and mortality when being used during pregnancy (2nd and 3rd trimesters).[2]
FDA modified its labeling on February, 2009 to include a precaution of drug interaction with gold. "Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including MONOPRIL/ MONOPRIL HCT."[3]
Dosage
The recommended initial dosage of Fosinopril/hydrochlorothiazide for adults with high blood pressure (hypertension) is losartan-hydrochlorothiazide 10 mg/12.5 mg per day. The dosage range could be 10-80 mg/12.5-50 mg once a day.
References
- ^ O'Grady P, Yee KF, Lins R, Mangold B (1999). "Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics". Br J Clin Pharmacol. 48 (3): 375–81. doi:10.1046/j.1365-2125.1999.00013.x. PMC 2014346. PMID 10510149.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ "fosinopril/hydrochlorothiazide (Rx)". Medscape. Retrieved 13 December 2013.
- ^ "Monopril HCT (fosinopril/hydrochlorothiazide) 20/12.5mg and 10/12.5mg Tablets February 2009". FDA.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |